

NCPE Assessment

Plain English Summary

December, 2025

Drug name: Tirzepatide
(pronounced Tur-ZEP-uh-tide) as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index of

- $\geq 30\text{kg/m}^2$ (obesity); **or**
- $\geq 27\text{kg/m}^2$ to $< 30\text{kg/m}^2$ (overweight) in the presence of at least one weight-related comorbid condition

Brand name: Mounjaro®

HTA ID: 24024

What is the NCPE?

The National Centre for Pharmacoeconomics (NCPE) is a team of experts who look at the health benefits and costs of medicines. The HSE asks us to advise on whether or not a new medicine is good value for money. We give unbiased advice to help the HSE provide the most effective, safe and cost-effective (value for money) treatments for patients.

How do we make our recommendations?

Our main focus is on the health benefits and cost effectiveness of a medicine. We look at the wider costs and health benefits associated with a new medicine, for example:

- Does the new medicine work better than other treatments available in Ireland?
- Is the new medicine easier to give or easier to take compared with other treatments available in Ireland?
- Does the new medicine reduce the need for patients to be hospitalised?
- Does the new medicine improve the quality of a patient's life over other treatments available in Ireland?
- Will the new medicine save resources elsewhere within the health system?

We review the information from clinical trials along with the cost and value for money data presented by the pharmaceutical company. We ask doctors and other healthcare professionals for advice about any health benefits of the new medicine compared with current treatments. We also ask patient organisations to send us their views on how the new drug may improve patients' day-to-day experience of living with a disease.

What is tirzepatide used for?

Tirzepatide is used together with diet and physical activity to help people to lose weight and keep their weight under control. It is used in people who have obesity (BMI of 30 kg/m² or more) or who are overweight (BMI between 27 and 30 kg/m²) and have weight-related health problems such as diabetes, abnormally high levels of fat in the blood, high blood pressure or obstructive sleep apnoea (frequent interruption of breathing during sleep).

What recommendation has the NCPE made to the HSE?

We have recommended that the HSE should consider funding tirzepatide (if its cost effectiveness (value for money) can be improved. The HSE will consider our recommendation and make the final decision about reimbursement (funding). When making the funding decision, the HSE will also consider the additional [criteria](#) outlined in the Health (Pricing and Supply of Medical Goods) Act 2013.

We have received a Patient Organisation Submission from the Irish Coalition for People Living with Obesity (ICPO) about tirzepatide and shared it with the HSE. This submission will form part of the data that the HSE considers.

Why did we make this recommendation?

After reviewing the data presented by the pharmaceutical company, we concluded that tirzepatide should be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments*.

We have completed a full health technology assessment for this medicine. We recommend that the HSE consider providing this medicine if the HSE can agree a suitable price reduction with the pharmaceutical company. We believe the medicine may work as well or better than other ways to manage this condition. However, the price of the medicine is too high compared with other ways to manage this condition, and we believe that the medicine is not value for money.

* The HSE considers a number of factors along with our recommendation when deciding whether to provide this medicine. These factors are listed in the Health (Pricing and Supply of Medical Goods) Act 2013.

Next steps

When the HSE receives our recommendation, it will look at all the relevant data about tirzepatide. The HSE makes the final decision on reimbursement.

Where can I get more information?

You can get more information about tirzepatide from the following online options:

- The NCPE Technical Summary Document
- Mounjaro® European Public Assessment Report (EPAR) – [Summary for the public](#)
- By searching for tirzepatide on our website (www.ncpe.ie)
- By searching for tirzepatide on the European Medicines Agency (EMA) website (www.ema.europa.eu).

Please refer to the NCPE website for updated information on the reimbursement status of this medicine